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Abstract
The Sherlock Holmes symposia have been educating haematologists on the need for prompt recognition, diagnosis and treatment of rare 
haematological diseases for 10 years. These symposia, which are supported by an unrestricted educational grant from Sanofi Genzyme, 
encourage haematologists to consider rare disorders in differential diagnoses. Improvement in rare disease awareness is important 
because diagnostics and the availability of effective therapies have improved considerably, meaning that rare haematological diseases 
can be accurately diagnosed and successfully managed, particularly if they are identified early. The Sherlock Holmes symposia programme 
includes real-life interactive clinical cases of rare haematological disorders that require awareness from the physician, to be diagnosed 
at an early stage. The audience are encouraged to examine each case as if they were detectives, look for clues from the clinical history 
and presentation, consider the potential causes, assess which tests would be required to make a definitive diagnosis and suggest optimal 
treatment options. To celebrate the 10-year anniversary of the Sherlock Holmes symposia, this article describes a number of clinical cases 
that include anaemia, thrombocytopaenia and splenomegaly among the presenting symptoms, to illustrate the importance of rigorous 
differential diagnosis in the identification of rare haematological disorders.
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Early diagnosis of rare haematological diseases
Rare haematological diseases often present ‘in disguise’, with non-
specific symptoms such as pancytopaenia, decreased circulating 
levels of one or two cell subsets and splenomegaly. Gaucher disease 
(GD) provides an excellent paradigm when considering challenges in 
diagnosing rare haematological diseases. Individuals presenting with 
GD will only rarely be seen regularly in the general haematology setting, 
even in areas with prominent Ashkenazi heritage communities. Such 
rare disorders require a more investigative approach to symptoms 
on the part of the haematologist. To assist diagnosis in such cases, 
the doctor should look for those features which do not match with 
the clinical picture of the usual underlying diseases. For most rare 
haematological diseases, including GD, sensitive and definitive 
confirmatory diagnostic tests are available, so confirming the diagnosis 
is relatively straightforward if the symptoms are recognised early.1 
Given the inherent difficulties in the diagnosis of these diseases, the 
Sherlock Holmes symposia were initiated as an educational initiative to 
raise awareness of rare haematological diseases. The symposia were 
designed to aid haematologists to recognise the symptoms of these 
diseases, to examine the clinical decision making required to support 
differential diagnoses, to identify appropriate confirmatory testing and 
to assist in recognising the need for early treatment intervention. 
Inspired by the Sherlock Holmes symposia, this article explores the 
diagnosis of rare haematological disorders by examining a number 
of informative real-life case studies with a focus on cases involving 
thrombocytopaenia and/or splenomegaly. 
Case study one – delay in diagnosis of rare 
haematological disorders
This case concerns a female with symptomatic GD who was 
undiagnosed for over 50 years (Table 1). Symptoms suggestive of GD 
in childhood and adolescence, such as splenomegaly, bone pain and 
borderline thrombocytopaenia were attributed to other conditions; 
for example, she received a diagnosis of osteomyelitis for the bone 
pain. This had a detrimental impact on the patient when she was in her 
20s, when she underwent splenectomy due to splenomegaly without 
any definitive diagnosis, as no histological evaluation of the spleen 
was available. Given that there is evidence that splenectomy can be 
detrimental in GD and may result in more aggressive disease in the liver, 
skeleton and lungs, the splenectomy may have had an ongoing adverse 
impact on the individual.2 Another clear opportunity for diagnosis was 
missed in the patient’s late 50s, when she presented with severe 
anaemia (haemoglobin [Hb] 80 g/l) and haemorrhagic episodes. At that 
stage, and despite the identification of Gaucher cells in a bone marrow 
biopsy, diagnosis was still delayed for a further six years. While this is 
an extreme example, diagnostic delay in GD is common. For example, 
a review of 136 patients with GD identified a mean diagnostic delay of 
10.3 ± 4.1 years from first onset of symptoms.3 The wide range of initial 
diagnoses in these patients included growing pains, lymphoma, liver 
disease, osteoporosis, fibromyalgia, collagenosis, cirrhosis, pituitary 
adenoma and Von Willebrand’s disease; indicating the difficulties 
facing physicians in formulating an initial diagnosis for GD. Similarly, 
the failure to recognise the classic symptoms of GD (cytopaenia, 
hepatosplenomegaly and bone pain) was identified by a global study 
of 406 haematologists/oncologists, which reported that only 20% 
considered GD in their differential diagnosis when presented with a 
patient exhibiting these symptoms.4 Instead, the majority of physicians 
considered leukaemia, lymphoma and multiple myeloma as the most 
likely diagnoses.4
Given that there are now effective therapeutic interventions for GD with 
both enzyme replacement therapies (ERT) and substrate replacement 
therapies (SRT) being available, it is particularly important that diagnostic 
delay is avoided and that early opportunities for intervention are not 
missed.5 This is critical, as treatment can reduce the risk of patients 
developing bone complications such as osteonecrosis, osteoporosis 
and lytic lesions, which are irreversible once they are established.1
Splenomegaly 
Enlargement of the spleen is a diagnostic clue to a number of conditions 
of diverse origin including infection, haematological malignancy, red cell 
disorders, metabolic conditions and other benign infiltrations (Table 2).6 
The clinician must integrate signs of splenomegaly with features of 
hypersplenism in the peripheral blood and other aspects of the clinical 
history, examination and investigations, in order to make a correct 
diagnosis of the underlying pathogenic mechanism. The following case 
identifies the importance of splenomegaly, both in the initial presentation 
and in the recognition of clinical deterioration due to underlying disease.
Case study two – splenomegaly in Gaucher 
disease and myelodysplastic syndrome
An active 36-year-old male presented with mild anaemia, 
thrombocytopaenia and high ferritin levels (1,400 ng/ml, normal 
Table 1: Delayed diagnosis of Gaucher disease 
in a 64-year-old female
Age/life 
stage









Abdominal discomfort and  
mild splenomegaly
Not thought to be of  
pathological significance
Nose bleeds Not considered unusual in  
children
Mild anaemia (haemoglobin:    
~115–120 g/l, normal  
120–150 g/l) and borderline 
platelets (140–135 x 109/l, 
normal 150–400 x 109/l)




10–14 years Acute bone pains Osteomyelitis diagnosis
20–30 years Chronic hepatitis 
 
 
Referred to a hepatologist.  
Mild anaemia and borderline 
platelets considered consistent 
with liver disease
Splenomegaly of unknown 
aetiology
Splenectomy 
Modest hepatomegaly,  
increase in transaminases  
and cholestasis parameters
Cryptogenic liver cirrhosis 





Severe anaemia and  
haemorrhagic episodes
Referred to a haematologist for 
the first time, who identified 
Gaucher cells in a bone marrow 
biopsy. No clinical intervention
60 years Worsening hepatomegaly  
(+14–19 cm); haemoglobin:  
60–80 g/l, normal 120–150 g/l;  
mild leukopaenia; near normal 
platelets; diffuse osteopaenia  
and coxarthrosis
No clinical intervention
64 years New referral. Acid beta-glucosidase 
assay performed. Gaucher disease 
diagnosis. Treatment options 
considered and individualised 
treatment plan initiated
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12–300 ng/ml). Two years previously, he was suspected of having genetic 
haemochromatosis but HFE gene testing discounted this diagnosis. 
The patient reported lack of energy and tiredness over a period of a 
few months, which restricted his sporting activities, but experienced no 
other symptoms except for mild, occasional peripheral sensory loss.
The patient had not received medication for the previous six 
months. Physical examination showed normal cardiovascular 
and respiratory function. The liver (4 cm) and spleen (3 cm) were 
palpable. Neurological examination showed wasting of foot muscles, 
decreased vibratory sensation below the knees, and loss of pain 
sensation. Biochemical laboratory tests showed: haemoglobin (Hb) 
125 g/l (normal 130–170 g/l); mean corpuscular volume (MCV) 81 
femtoliters/cell (normal 80–100 fL); white blood cells (WBC) 6.2 x 109/l 
(normal 4–10 x 109/l); thrombocytopaenia (platelets 88 x 109/l) 
(normal 150–400 x 109/l); aspartate aminotransferase (AST) 67 U/l 
(normal 5–30 U/l); alanine aminotransferase (ALT) 89 U/l (normal 
5-30 U/l); gamma-glutamyltransferase (gGT) 35 U/l (6–50 U/l); 
total bilirubin 1.7 mg/dl (normal 0.3–1.2 mg/dl), unconjugated bilirubin 
1.3 mg/dl (normal 0.2–0.7 mg/dl); iron 84 µg/dl (50–175 µg/dl); 
transferrin saturation 30% (normal 20–50%); ferritin 1400 ng/ml (normal 
12–300 ng/ml); hepatitis C virus (HCV) and hepatitis B surface antigen 
negative; blood film normocytic/microcytic cells; poikilocytosis; 
glucose-6-phosphate dehydrogenase (G6PD) activity was normal. 
A liver biopsy was performed, which showed Gaucher cells (Figure 1). 
Diagnosis of GD type 1 was confirmed by glucocerebrosidase activity 
in leucocytes (2.2 nm/mg/h, normal 11.5 + 3.6). Chitotriosidase activity 
was 1.48 nm/mg/h (normal 25.75 + 17); genetic analysis: N370S/P401L.
The patient started enzyme replacement therapy (ERT) at 30 U/
kg/2 weeks. After one year of treatment, organomegaly (evaluated 
by magnetic resonance imaging) and haematological parameters 
had improved significantly: Hb: 135 g/l (normal 130–170 g/l); 
MCV 83 fl; WBC 6.7 x 109/l (normal 4–10 x 109/l); neutrophils 
5.7; lymphocytes 3.4; platelets 137 x 109/l (normal 150–400 
x 109/l); AST 27 U/l (normal 5–30 U/l); ALT 27 U/l (normal 
5–30 U/l); gGT 35 U/l (normal 6–50 U/l); total bilirubin: 1.0 mg/dl 
(normal 0.3–1.2 mg/dl), unconjugated bilirubin: 0.7 mg/dl (normal 
0.2–0.7 mg/dl); iron: 118 mg/dl (50–175 µg/dl); transferrin saturation 28% 
(normal 20–50%); ferritin: 475 ng/ml (normal 12–300 ng/ml) (Table 3). 
The patient did well until September 2010, when he complained of 
marked asthenia, fever and bone pain. Haematological parameters 
worsened: Hb 103 g/l (normal 130–170 g/l); WBC 23.48 x 109/l (normal 
4–10 x 109/l); (neutrophils 85%, lymphocytes 11%, blasts 2%; erythroblasts 
3%); platelets 173 x 109/l (normal 150–400 x 109/l); lactate dehydrogenase 
(LDH) 1115 U/l (normal 135–225 U/l); C-reactive protein (CRP) 0.2 mg/dl 
(normal <0.50 mg/dl). He had mild hepatomegaly and an enlarged spleen 
(17.3, 5 cm below the costal margin). Due to increased leukocytes, high 
LDH and blasts in peripheral blood and reappearance of anaemia, a bone 
marrow aspirate and bone marrow biopsy were performed.
An ‘unclassifiable myelodysplastic syndrome’ was diagnosed with 
an unfavourable karyotype: 46XY, del (3)(q21), del (20)(q12) according 
Table 2: Differential diagnosis for 
splenomegaly6
Cause of splenomegaly Clinical differentials
Infections Bacterial, viral, fungal or parasitic
Infiltrating diseases Glycogen storage diseases, amyloidosis, systemic 
mastocytosis, splenic metastasis 
Immunological disorders 
 
Felty’s syndrome, systemic lupus erythematosus, 





Elevated splenic vein 
pressure
Liver cirrhosis, hepatic vein obstruction, portal vein 
obstruction, splenic vein thrombosis 
Liver cirrhosis Hepatitis, chronic alcohol abuse, non-alcoholic fatty 
liver disease
Metabolic diseases Gaucher disease, Niemann Pick B, C, etc.
Haematological 
malignancies 
Chronic lymphocytic leukaemia (CLL), lymphomas, 
acute lymphocytic leukaemia, myeloproliferative 
disorders, acute myeloid leukaemia
Figure 1: H and E stained liver biopsy showing 
Gaucher cells 
Image provided by MD Cappellini.
Table 3: Haematological parameters before 
and after enzyme replacement therapy






Haemoglobin, g/l 125 135 130–170
Mean corpuscular volume, fl 81 83 80–100
White blood cells, x109/l 6.2 6.7 4–10
Thrombocytopaenia, x109/l 88 137 150–400
Aspartate aminotransferase, U/l 67 27 5–30
Alanine aminotransferase, U/l 89 27 5–30
Gamma-glutamyltransferase, U/l 35 35 6–50
Total bilirubin, mg/dl 1.7 1.0 0.3–1.2
Unconjugated bilirubin, mg/dl 1.3 0.7 0.2–0.7
Iron, µg/dl 84 118 50–175
Transferrin saturation, % 30 28 20–50
Ferritin, ng/ml 1400 475 12–300
ERT = enzyme replacement therapy.
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to World Health Organization (WHO 2008) classification system.7 The 
patient started hydroxyurea (500 mg) with blood transfusion support 
while continuing ERT at the same dosage. During the next few months 
he had repeated infections. Haematological status remained stable 
until July 2011, when azacitidine was initiated in response to a 
significant increase in leukocytes (54 x 109/l, normal 4–10 x 109/l) with 
blast cells in peripheral blood and platelets increased (691 x 109/l, 
normal 150–400 x 109/l).8 The patient was admitted to hospital for 
investigation. A bone marrow biopsy showed a significant increase 
in blast cells suggesting evolution to overt acute myeloid leukaemia 
(AML). He was treated with induction chemotherapy and achieved 
clinical remission. However, despite the use of intensive consolidation 
strategies with high-dose cytarabine, he relapsed and died due to the 
secondary AML.
In this case, the initial identification of GD allowed effective therapy to 
be initiated, however, the patient deteriorated due to a myelodysplastic 
syndrome and AML, which was identified following worsening 
haematological parameters and marked splenomegaly. 
Thrombocytopaenia 
A reduced platelet count is a diagnostic clue to a number of 
conditions of diverse origin such as rare congenital and, in particular, 
acquired thrombocytopaenias, infection, haematological malignancy, 
immunological disorders, viral infections and metabolic disorders 
(Table 4).9 Diagnosis based on the clinical presentation and history 
should start with an evaluation of all blood counts and confirmation 
of thrombocytopaenia, including investigation of the peripheral blood 
smear.9 After also taking into account the severity of bleeding, the 
need for therapeutic intervention or further diagnostic testing should 
be assessed.9 The following case illustrates the diagnostic process 
for a patient who presented with haemolytic anaemia, haematuria 
and thrombocytopaenia.
Case study three – 17-year-old male with 
haemolytic anaemia, haematuria and 
thrombocytopaenia
A 17-year-old male presented with chronic haemolytic anaemia, 
proteinuria, haematuria and hypertension. Initial laboratory results 
showed anaemia (Hb 102 g/l, normal 130–160 g/l), raised reticulocytes 
(2.6%, normal 0.5–2%), thrombocytopaenia (110 x 109/l, normal 
150–450 x 109/l), moderate splenomegaly (15 cm),10 enlarged kidneys 
with normal arteries and pronounced macroscopic haematuria. 
Given the initial findings, bone marrow and kidney biopsies were 
performed. The bone marrow smear showed normal cell counts, 
with normal megakaryopoiesis, slight maturation retardation in the 
granulopoiesis and slightly increased erythropoiesis. This confirmed 
the thrombocytopaenia in this patient was not due to a production 
defect, but was due to platelet degradation in the circulation. The renal 
biopsy showed a chronic thrombotic microangiopathic nephropathy. 
Haemolytic uremic syndrome (HUS) and thrombocytopaenic 
purpura (TTP) can have a range of causes, but in this patient 
hyperhomocysteinaemia of three- to four-times the upper limit of 
normal and mild methylmalonic aciduria was suggestive of a Cobalamin 
C/D (Cbl-C/D) defect. Fibroblast studies and genetic testing of the 
methylmalonic aciduria and homocystinuria type C protein (MMACHC) 
gene confirmed Cbl-C defect. The patient’s nine-year-old sister was 
diagnosed with the same disorder at a pre-symptomatic stage. 
Following diagnosis parenteral high-dose hydroxycobalamin injections 
(0.5 mg/kg/day) reduced the homocysteine levels, and methylmalonic 
acid disappeared from the urine in both the index case and his sister. 
Treatment addressed the haemolysis, haematuria and proteinuria and 
creatinine clearance has been stable for over 18 years. 
The initial presentation of thrombocytopaenia with anaemia, raised 
reticulocytes, splenomegaly, enlarged kidneys and haematuria, 
exemplifies the non-specific symptomology often encountered in 
patients with haematological disorders. In this case bone-marrow 
and kidney biopsies were performed to provide further clinical clues 
and these identified thrombotic microangiopathic nephropathy. 
The diagnosis of a Cbl-C/D defect can be made by widely available 
blood and urine testing for homocysteine and methylmalonic acid 
respectively. Therefore, if testing for the more common reasons for 
chronic thrombotic microangiopathy have failed to identify causation, 
testing for Cbl-C/D defect, which is an unusual but treatable inborn 
cobalamin metabolism disorder, may be appropriate.11
Gaucher disease 
GD is an autosomal recessive inherited disease caused by mutations 
in the gene for glucocerebrosidase (GBA1), which is estimated to affect 
around 1 in 57,000 births.12 The prevalence is higher in individuals with 
Ashkenazi heritage (~1 in 800).1 The defect in glucocerebrosidase 
leads to the accumulation of glucocerebroside in the lysosomes of 
macrophages (Gaucher cells).3 Gaucher cells can be identified by their 
eccentrically placed nuclei and cytoplasm with characteristic crinkles 
and striations, although Gaucher cells with atypical cytomorphology 
have been described.13–15
GD is classified into three broad phenotypes, although clinical 
presentation can be highly variable, even in patients with the same type.16 
Type I (nonneuronopathic) GD typically presents with splenomegaly, 
thrombocytopaenia, anaemia, hepatomegaly, pulmonary disease 




• Congenital conditions 
    –    Megakaryocytic hypoplasia, Bernard-Soulier 
syndrome, Wiskott-Aldrich and May-Hegglin 
syndrome, Fanconi’s syndrome
• Viral infections
    –    Herpes simplex, cytomegalovirus, varicella-zoster, 
Epstein-Barr, rubella, enterovirus, mumps,  
hepatitis, HIV
• Haematological malignancies
    –   Leukaemia, lymphoma, myeloma, myelodysplasia
• Some forms of bone marrow failure
    –   Aplastic anaemia, megaloblastic anaemia
• Alcoholism (folic acid deficiency)
• Toxic chemicals/some drugs 
Hypersplenism • Gaucher disease 
• Myelofibrosis
• Cirrhosis with spleen enlargement
Platelet destruction/
dilution
• Immune thrombocytopaenia 
• Pregnancy
• Neonatal alloimmune thrombocytopaenia 
• Common variable immune deficiency
• Lymphoproliferative disorders
• Thrombotic thrombocytopaenic purpura
• Consumption due to blood loss 
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and skeletal disease (osteopenia, osteoporosis, bone remodelling 
abnormalities [the classic Erlenmeyer flask deformity], pathological 
fractures, osteolytic lesions and osteonecrosis). Rare neuronopathic variants 
(type 2 acute neuronopathic and type 3 chronic neuronopathic disease) 
demonstrate neurodegeneration in addition to the other symptoms.16 
Individuals with GD have an increased risk of developing certain cancers, 
especially multiple myeloma and other plasma cell neoplasms, but 
also other haematological and lymphoid malignancies, hepatocellular 
carcinoma and renal cell carcinoma.17,18 GD is associated with an 
increased risk of cancer with a rate ratio (RR) of 2.5 (95% CI 1.1–4.7) and 
an increased RR of haematologic cancer of 12.7 (95% CI 2.6–37.0) 
compared with the general population.19 The risk of multiple myeloma 
is particularly high in GD with rate ratios of 51.1 (95% CI 6.2–184) 
compared with the general population.19 Many manifestations of GD 
are common to multiple myeloma, such as cytopaenia, the presence 
of lipid laden macrophages (pseudo Gaucher cells) in the bone 
marrow, monoclonal gammopathies, bone remodelling abnormalities 
and bone destruction due to aberrant cytokine release.1,3,20 Monoclonal 
gammopathy of undetermined significance (MGUS) has been reported 
in 19% of Gaucher patients.21 Low-risk MGUS is characterised by a 
monoclonal protein <15 g/l, IgG type and a normal free light chain 
ratio (risk of progression 1% per year).22
Diagnosis is delayed in approximately 25% of patients with GD due 
to the non-specific and heterogeneous symptoms and the rarity of 
the disease.1 Given that the enzyme test provides a clear diagnosis, 
treatment algorithms have been published to assist physicians in 
identifying GD (Figure 2).1 The higher prevalence of GD in individuals 
with Ashkenazi heritage, means that enzyme testing should be 
performed as a first-line investigation in anyone with such heritage 
presenting with splenomegaly and cytopaenia.1 The N370S mutation, 
a common genotype in Askenazi populations, is often associated with 
mild cytopaenia and splenomegaly that can escape initial detection; 
therefore, symptoms associated with GD such as hyperferritinaemia, 
low low-density lipoprotein (LDL) and high-density lipoprotein (HDL) 
cholesterol, premature gallstones or osteoporosis and gammopathy 
should prompt the clinician to consider enzyme testing.1 
In non-Ashkenazi populations, haematological malignancies are more 
common than GD, so GD should be considered in the differential 
diagnosis after malignancies have been ruled out.1 In this setting, 
bone marrow biopsy is usually performed; and it should be routine 
to search for Gaucher cells as well as for evidence of haematological 
malignancies (Figure 2).1 Portal hypertension due to advanced liver 
disease from well-known etiologies must also be ruled out before 
application of the algorithm.1 
Treatment
Symptomatic GD should be treated with ERT such as imiglucerase 
(Cerezyme®; Sanofi Genzyme, Cambridge, MA, US), velaglucerase alfa 
(VPRIV®; Shire HGT, Cambridge, MA, US) or taliglucerase alfa (Elelyso®; 
Protalix Biotherapeutics, Carmiel, Israel and Pfizer, NY, USA).23 ERT 
ameliorates or reverses many systemic manifestations of GD and 
is generally accepted as the first-line therapy for GD.5,23 However, it 
does not fully address all the coagulopathies in GD and therapeutic 
interventions should be considered to treat and/or prevent bleeding.24 
In addition, some patients experience ongoing bone disease during ERT 
and in these patients adjunctive therapy with bisphosphonates may 
help improve bone mineral density.25 
An alternative therapeutic approach is to use an SRT, such as miglustat 
(Zavesca®; Actelion Pharmaceuticals Ltd., Allschwil, Switzerland) or 
eliglustat (Cerdelga®; Sanofi Genzyme, Cambridge, MA, United States),26 
which addresses the deficiency of the enzyme glucocerebrosidase in 
GD by slowing down the production of glucocerebroside. In a phase III 
trial, eliglustat treatment for nine months significantly improved spleen 
volume, haemoglobin level, liver volume and platelet count versus 
placebo in previously untreated individuals with GD.27 In a second, open-
label, phase III trial, eliglustat maintained haematological and organ 
volume stability and was non-inferior to imiglucerase in individuals 
with GD previously stabilised with ERT.28 Eliglustat is approved as first-
line treatment for GD type 1 in Europe and the United States, giving the 
option of a daily oral treatment rather thanintravenous ERT infusions.29  
Miglustat is indicated for the oral treatment of adult patients with mild to 
moderate type 1 Gaucher disease and may be used only in the treatment 
of patients for whom enzyme replacement therapy is unsuitable.35
Figure 2: Differential diagnosis of GD in 
patients of Ashkenazi Jewish origin (A) and 
non-Ashkenazi Jewish origin (B)1
Leucocyte acid β-glucosidase assay 
Signs and symptoms 
supporting a suspicion 
of Gaucher disease: 
History of: 
– Gall stones 
– Abdominal discomfort 
– Low cholesterol 
– Hyperferritinemia 
– Splenic nodules 
– Pregnancy associated 
   thrombocytopaenia 
– Postpartum 
   haemorrhage 






Yes to one or more 
•  Low platelets? 
•  Unexplained 
    bleeding tendency? 
•  Unexplained stable 
    hyperferritinemia + 
    normal transferrin 
    saturation? 
•  Increased 
    inammatory 
    markers? 








– Gall stones 
– Abdominal 
   discomfort 
– Low cholesterol 
– Hyperferritinemia 
– Splenic nodules 
– Pregnancy 
   associated 
   thrombocytopaenia 
– Postpartum 
   haemorrhage 










Examine biopsy for 
Gaucher cells
Platelets <150k ±
bone pain ± MGUS/
polygammopathy




















MGUS = Monoclonal gammopathy of undetermined significance. From Mistry PK et al, 
Am J Hematol, 2011;86:110–5.1 Copyright © 2010 by John Wiley & Sons, Inc. Reprinted 
by permission of John Wiley & Sons, Inc.
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The impact of Gaucher-specific therapy on the development of 
multiple myeloma is unknown. Polyclonal gammopathy may decrease 
with ERT,4 but the impact of ERT on monoclonal gammopathies is 
inconclusive.21,30 Follow-up of individuals with GD and monoclonal 
gammopathies should be performed at least every year using 
serum protein electrophoresis free light chains estimation and 
serum and urine immunofixation. If monoclonal IgG exceeds 15g/l, a 
bone marrow aspirate should be carried out to check for malignant 
transformation.31 Bone marrow aspirate and biopsy are helpful in 
patients with concomitant GD and myeloma in estimating the reserve 
of haematopoietic tissue. Induction and consolidation therapy using, 
proteasome inhibitors, cyclophosphamide, immunomodulatory 
drugs, such as thalidomide or lenalidomide, are feasible.31 Because 
chemotherapy may aggravate cytopaenia, ERT should be initiated 
in Gaucher patients with myeloma to enable treatment. Supportive 
therapy using biphosphonates may be appropriate.
 
Case study four – multiple myeloma and 
Gaucher disease 
A 67-year-old male patient presented with bone pains, fatigue and nasal 
bleeding. Physical examination revealed an enlarged spleen. Laboratory 
investigation showed anaemia (Hb: 90 g/l, normal 130–170 g/l) 
and thrombocytopaenia (platelets 90 x 109/l, normal 150–400 x 109/l). 
WBC and differential counts were normal. Biochemical investigations 
showed normal renal clearance and liver function; hypercalcaemia 
(serum calcium 11.2 mg/dl, normal range: 8.7–10.5 mg/dl) and increased 
total serum proteins: 13.8 g/dl (normal 6.0–8.3 g/dl) with albumin 3.4 g/dl 
(normal 3.5–5.0 g/dl). Serum protein electrophoresis and immunofixation 
revealed a monoclonal IgGκ of 12.8 g/l. Quantitative immunoglobulin 
assays revealed IgG of 34.8 g/l (normal 7–16 g/l), IgM of 1.14 g/l (normal 
0.4–2.3 g/l) and IgA of 0.59 g/l (normal 0.85–4.5 g/l), free light chains 
(FLC) κ/λ ratio 10.9 (normal 1.35–2.67). Bence-Jones protein was 
demonstrated in urine. Results of 24-hour urinalysis showed proteinuria 
(0.79 g: normal <0.15 g) with κ/λ ratio of 37.78 (normal 0.75–4.0) kappa 
light chain quantification 150 mg/l (normal <7.1). Serum β2-microglobulin 
was 8.75 (normal <2.5 mg/l). Radiography showed multiple lytic lesions 
in the skull, diffuse osteopenia of the femur, and the Erlenmeyer flask 
deformity of the distal femur. Dual energy X-ray revealed osteoporosis. 
Findings suggested a diagnosis of multiple myeloma IgGκ, classified 
as stage IIA according to the Durie and Salmon system and stage III 
according to the International Staging (ISS) system.32 Bone marrow 
aspiration was unsuccessful (dry tap) and a trephine bone marrow 
biopsy was performed to confirm the diagnosis.
The splenomegaly remained unexplained. A computed tomography scan of 
the upper abdomen confirmed the splenomegaly (diameter 18.5 cm); there 
was no hepatomegaly or enlarged lymph nodes. Splenomegaly was not 
associated with lymphoma (no enlarged lymph nodes), chronic lymphocytic 
leukaemia (no lymphocytosis), or Waldenström macroglobulinaemia (no 
monoclonal IgM paraprotein). Differential diagnosis was considered for 
splenomegaly (bacterial, viral fungal or parasitic infection, liver cirrhosis, 
autoimmune haemolytic anaemia, spherocytosis, metabolic disease, 
amyloidosis etc.). The observation of the Erlenmeyer flask deformity and 
increased plasma chitotriosidase (16,817 nmol/ml/hr; normal <200 nmol/
ml/hr) finally led to suspicion of GD.
The bone marrow biopsy performed at diagnosis revealed Gaucher 
cells, which greatly replaced granulo-, erythro- and thrombopoiesis, 
and about 15% monoclonal plasma cells positively stained with 
IgG and kappa antibody. GD was confirmed by enzyme assay (low 
ß-glucocerebrosidase 2.6 nmol/mg prot/hr, normal 6–23 nmol/mg prot/
hr) and by genotyping (N370S/L444P).
Case study five – Gaucher disease and 
smouldering multiple myeloma
A 66-year-old male was diagnosed with GD when he was 45 years 
of age (genotype: N370S/N370S) following the identification of 
mild thrombocytopaenia during a routine blood count. He had a 
history of nephrectomy for renal carcinoma. In 2004 (aged 58), he 
presented with bone pain, hepatosplenomegaly, osteoporosis and a 
platelet count of 40–60 × 109/l (normal 150–400 × 109/l) . Laboratory 
investigations showed two monoclonal spikes: IgGκ 2.8 g/l and IgAκ 
1.12 g/l and light chain proteinuria (Bence-Jones κ protein: 0.45 g/24h). 
Hb, creatinine and calcium levels were within normal values. Bone 
imaging showed osteolytic lesions and a well-defined mass, most 
probably a bone infarct or a ‘Gaucheroma’ (a mass of Gaucher cells) 
in the right humerus. Bone marrow aspirate and biopsy revealed 15% 
CD138 positive and monoclonal plasma cells with a normal karyotype 
on a cytogenetic study. The patient was diagnosed with concomitant 
GD and smouldering multiple myeloma.
Treatment with ERT and bisphosphonates was initiated. Two years later, 
spleen and liver volume had normalised, platelets were 100 x 109/l 
(normal 150-400 × 109/l), kidney function tests were normal and he was 
free of bone pain. After nine years, osteoporosis has improved and 
monoclonal spikes and light chain proteinuria are stable.23
The risk of multiple myeloma is particularly high in GD and both diseases 
share common symptoms.1,3,19,20 These two cases highlight the importance 
of considering early detection of MGUS, multiple myeloma or amyloidosis 
in individuals diagnosed with GD. Additionally, GD should be considered in 
relatively young patients diagnosed with multiple myeloma, smouldering 
myeloma or MGUS. The diagnosis and treatment of concomitant GD and 
myeloma is challenging. Immunophenotyping and cytogenetic testing of 
bone marrow specimens are essential for the diagnosis of myeloma in 
a marrow infiltrated with Gaucher cells. ERT should be initiated in GD 
patients with myeloma in order to prevent aggravation of cytopaenia 
due to chemotherapy. A search for monoclonal gammopathy should 
be systematically (and periodically) done in patients with GD given the 
increased susceptibility to plasma-cell neoplasm.
Case study six – warfarin-like poisoning
A 56-year-old woman was investigated for bruising and recent gum 
and skin bleeds. The patient had no relevant medical history, was 
not taking any medications and had a normal diet. Following clinical 
investigation, an isolated prolongation of prothrombin time was detected, 
and deficiency of all vitamin K-dependent clotting proteins. Only after a 
third interview, when the patient indicated that she used rat poison to 
prevent the rats from eating the food for the hamsters but forgot to wash 
her hands before having lunch, did the doctor realise that the woman’s 
bruising could be related to warfarin-like poisoning and the effects of 
vitamin K antagonists.
An overview of vitamin K antagonists
Vitamin K antagonists were first identified in 1941 and while the 
potential clinical value was recognised from the outset, the synthesis 
of the vitamin K antagonist warfarin was ﬁrst exploited as a rodent 
poison. Vitamin K antagonists interfere with the synthesis of vitamin 
K-dependent proteins, including the clotting proteins prothrombin, 
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factor II, VII and X, and have major anti-thrombotic effects.33 In this case 
the exposure was accidental as the patient was using warfarin as a 
rodenticide to deal with her rat infestation.
Key clinical signs
The most sensitive test for the effect of vitamin K antagonists is the 
prothrombin time, sensitive to the levels of three of the four vitamin 
K-dependent clotting proteins (VII, X and prothrombin). The International 
Normalised Ratio (INR) is a form of standardised prothrombin time. 
The prolongation of the partial thromboplastin time is usually not as 
severe as the prothrombin time.
Warfarin at a dose of 5–10 mg a day induces severe depletion of 
factor VII in one to two days. Shortly thereafter, factor IX, X and prothrombin 
levels will also fall. Lower doses will also result in the same low levels but 
after a longer period of time. The regular inadvertent intake of vitamin 
K antagonists (as in the exposure to rat poison) is seldom reported. The 
clinical effect depends on the vitamin K intake of the individual.
Treatment
The effects of vitamin K antagonists are counteracted by administration 
of extra vitamin K.34 In general, 10 mg per day for a few days will be 
sufﬁcient (depending on the t1⁄2 of the causative compound). In the 
case of acute severe bleeding, clotting proteins may be administered.
Summary
The recognition of rare haematological diseases is challenging. Given 
that these diseases often initially present with fairly non-specific 
haematological symptomology, haematologists are likely to face these 
challenging diagnoses in their clinical practice. Therefore, it is important 
for haematologists to have an awareness of rare haematological 
diseases and to consider them when making their initial differential 
diagnoses based on information obtained from the patient, the clinical 
findings and laboratory values. As the cases reviewed here show, once 
the possibility of a rare haematological disease has been identified, 
confirmatory testing is relatively straightforward in the majority of cases. 
In addition, as effective therapeutic interventions are available for many 
of these conditions, it is important that patients are not denied effective 
treatment due to diagnostic delays. Over the last 10 years, the Sherlock 
Holmes symposia have raised the awareness of rare haematological 
diseases among thousands of haematologists around the world. Through 
the greater disease awareness promoted by these symposia, it is hoped 
that many patients already have and will benefit from earlier recognition 
and treatment for their rare haematological diseases. ■
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